We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$12B
AUM Growth
+$251M
Cap. Flow
-$39.8M
Cap. Flow %
-0.33%
Top 10 Hldgs %
36.53%
Holding
164
New
29
Increased
43
Reduced
30
Closed
27

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$255M
2
BSX icon
Boston Scientific
BSX
+$146M
3
ABBV icon
AbbVie
ABBV
+$121M
4
AGN.PRA
Allergan plc
AGN.PRA
+$109M
5
PBYI icon
Puma Biotechnology
PBYI
+$103M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$207M
2
ZBH icon
Zimmer Biomet
ZBH
+$116M
3
MDVN
MEDIVATION, INC.
MDVN
+$115M
4
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$105M
5
SYK icon
Stryker
SYK
+$87.8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.53%
2 Financials 0.24%
3 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABT icon
101
Abbott
ABT
$191B
$10.4M 0.09%
211,000
– –
MCRB icon
102
Seres Therapeutics
MCRB
$45.9M
$10.2M 0.09%
+12,332
New +$10.8M
ONCE
103
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$10M 0.08%
166,500
+39,500
+31% +$2.61M
ANAC
104
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$9.99M 0.08%
+129,000
New +$8.46M
RDHL
105
Redhill Biopharma
RDHL
$4.26M
$9.95M 0.08%
565
-121
-18% -$1.92M
IOVA icon
106
Iovance Biotherapeutics
IOVA
$2.02B
$9.37M 0.08%
1,022,100
+22,100
+2% +$247K
ROKA
107
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$8.37M 0.07%
322,043
– –
OSUR icon
108
OraSure Technologies
OSUR
$275M
$8.36M 0.07%
1,550,300
-428,200
-22% -$2.65M
AGN
109
CALL
DELISTED
Allergan plc
AGN
$7.59M 0.06%
25,000
-475,000
-95% -$142M
ALIM
110
DELISTED
Alimera Sciences
ALIM
$6.92M 0.06%
100,000
– –
IPXL
111
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
$6.89M 0.06%
150,000
+50,000
+50% +$2.37M
NVTA
112
DELISTED
Invitae Corporation
NVTA
$6.79M 0.06%
456,666
– –
PTX
113
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$6.35M 0.05%
107,300
– –
BITI
114
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$5.37M 0.04%
+268,672
New +$5.61M
FATE icon
115
Fate Therapeutics
FATE
$267M
$4.48M 0.04%
692,900
– –
ADVM
116
CALL
DELISTED
Adverum Biotechnologies
ADVM
$4.06M 0.03%
+25,000
New +$8.43M
ARRY
117
CALL
DELISTED
Array Biopharma Inc
ARRY
$3.6M 0.03%
500,000
-600,000
-55% -$4.43M
BLRX
118
BioLineRX
BLRX
$12.3M
$3.02M 0.03%
1,892
– –
MNKD icon
119
PUT
MannKind Corp
MNKD
$1.21B
$2.56M 0.02%
+90,000
New +$2.3M
PDLI
120
CALL
DELISTED
PDL BioPharma, Inc.
PDLI
$2.44M 0.02%
+380,000
New +$2.55M
PTCT icon
121
PUT
PTC Therapeutics
PTCT
$6.15B
$2.41M 0.02%
+50,000
New +$2.92M
SGYP
122
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.08M 0.02%
+250,000
New +$1.21M
QLTI
123
DELISTED
QLT Inc
QLTI
$2.06M 0.02%
+500,000
New +$1.92M
CARM
124
DELISTED
Carisma Therapeutics
CARM
$2.06M 0.02%
+36,580
New +$5.16M
DRNA
125
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.98M 0.02%
141,900
-53,100
-27% -$974K
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2015 Portfolio in Review

As of Q2 2015, OrbiMed held 164 positions worth $12B, up 2.1% from $11.7B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q2 2015 filing shows 29 new, 43 increased, 30 reduced and 27 closed positions. Its largest new stake was Allergan plc: 104,200 shares worth $109M. The largest sale was Perrigo, an estimated $207M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2015 buy was Allergan plc: 104,200 shares worth $109M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2015, an estimated $255M increase.
  • OrbiMed's biggest Q2 2015 reduction was Zimmer Biomet, cutting an estimated $116M.
  • OrbiMed fully exited Perrigo in Q2 2015, selling an estimated $207M.
  • OrbiMed's ten largest holdings make up 37% of its $12B portfolio in Q2 2015.
  • OrbiMed opened 29 new positions and closed 27 in Q2 2015.
  • OrbiMed's portfolio value rose 2.1% quarter-over-quarter to $12B.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.